E
78.54
0.41 (0.53%)
| Previous Close | 78.12 |
| Open | 77.84 |
| Volume | 1,020,788 |
| Avg. Volume (3M) | 4,690,641 |
| Market Cap | 45,613,129,728 |
| Price / Earnings (TTM) | 43.39 |
| Price / Earnings (Forward) | 26.25 |
| Price / Sales | 7.52 |
| Price / Book | 4.34 |
| 52 Weeks Range | |
| Earnings Date | 23 Apr 2026 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bullish |
AIStockmoo Score
0.2
| Analyst Consensus | 5.0 |
| Insider Activity | -3.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.20 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Stifel, 40.07%) | Buy |
| Median | 100.00 (27.33%) | |
| Low | 89.00 (Truist Securities, 13.33%) | Hold |
| Average | 99.50 (26.70%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 80.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 11 Feb 2026 | 103.00 (31.15%) | Buy | 79.33 |
| Goldman Sachs | 11 Feb 2026 | 95.00 (20.97%) | Buy | 79.33 |
| Piper Sandler | 11 Feb 2026 | 100.00 (27.33%) | Buy | 79.33 |
| 20 Jan 2026 | 98.00 (24.79%) | Buy | 83.46 | |
| Truist Securities | 11 Feb 2026 | 89.00 (13.33%) | Hold | 79.33 |
| Wells Fargo | 11 Feb 2026 | 100.00 (27.33%) | Buy | 79.33 |
| Stifel | 20 Jan 2026 | 110.00 (40.06%) | Buy | 83.46 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LIPPIS DANIEL J. | - | 81.19 | -1,019 | -82,733 |
| ULLEM SCOTT B. | - | 79.15 | -13,000 | -1,028,950 |
| Aggregate Net Quantity | -14,019 | |||
| Aggregate Net Value ($) | -1,111,683 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 80.17 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ULLEM SCOTT B. | Officer | 09 Apr 2026 | Automatic sell (-) | 13,000 | 79.15 | 1,028,950 |
| ULLEM SCOTT B. | Officer | 09 Apr 2026 | Option execute | 13,000 | - | - |
| LIPPIS DANIEL J. | Officer | 06 Apr 2026 | Automatic sell (-) | 1,019 | 81.19 | 82,733 |
| LIPPIS DANIEL J. | Officer | 06 Apr 2026 | Option execute | 1,019 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026 |
| 02 Feb 2026 | Announcement | Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |